India · Delayed Price · Currency is INR Vimta Labs Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 delivered robust growth in core pharma and food testing, with EBITDA margins among the industry's best and a net debt-free balance sheet. Strategic entry into biologics and a new U.S. subsidiary position the company for future expansion, despite global uncertainties.
-
Q3 FY26 revenue grew 10.2% year-over-year, led by pharma and food testing, though operational delays deferred some revenue. Nine-month EBITDA margin was 35.1%, with exports rising to 39% of income. Biologics services launch in Q1 FY27, and Q4 is expected to be seasonally strong.
-
Record Q2 FY26 revenue and profit growth were driven by pharma and food testing, with strong margins and a net debt-free position. Capacity expansions and CapEx support future growth, especially in biologics, while both domestic and export markets contribute to momentum.
-
Q1 FY26 saw record revenue of INR 993 million, up 31.4% year-on-year, with strong EBITDA margin of 35.7% and profit after tax up 35.9%. Growth was broad-based across pharma, food, and electronics testing, with robust export gains and a 1:1 bonus issue approved.
Fiscal Year 2025
-
Revenue grew 19.1% year-over-year in FY2025, led by pharma services and strong export growth. Margins improved, CapEx guidance is INR 900 million for FY2026, and a major expansion into biologics CDMO is underway. Repeat business remains above 90%.
-
Q2 FY25 saw 26.4% YoY revenue growth, driven by pharma services and improved margins post-diagnostics divestment. The company targets a 500 crore run rate in FY26, with sustainable mid-30% EBITDA margins and ongoing capacity expansion.
-
Q1 FY25 saw stable performance with 3% sequential revenue growth, strong margins, and continued capacity constraints. New Hyderabad facility and CapEx are set to drive growth, with management targeting INR 500 crore revenue by FY26.